Plasma coagulation profiles in patients with severe primary pulmonary hypertension

European Respiratory Journal

Volumn 12, Issue 6, 1998, Pages 1446-1449

  Hoeper, M M ^a   Sosada, M ^b   Fabel, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Krankenhaus Siloah   (Germany)

Author keywords

Coagulation; Fibrinolysis; Plasma activator inhibitor; Primary pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN DEGRADATION PRODUCT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOSIS;

ANTITHROMBIN III; BLOOD COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; HYPERTENSION, PULMONARY; PEPTIDE HYDROLASES; PLASMINOGEN INACTIVATORS; PROTEIN C; PROTEIN S; THROMBIN; VON WILLEBRAND FACTOR;

EID: 0032441560     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12061446     Document Type: Article

References (17)

1. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diasnosed cases. Circulation 1970; 42: 1163-1184.
2. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25.
3. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
4. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.
5. Welsh CH, Hassell KL, Badesch D, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110: 710-717.
6. Boyer-Neumann C, Brenot F, Peynaud-Debayle E, et al. Continuous infusion of prostacyclin decreases plasma levels of t-PA and PAI-I in primary pulmonary hypertension. Thromb Haemast 1995; 4: 727-738.
7. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933.
8. Eisenberg PR, Lucore L, Kaufman E, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in primary pulmonary hypertension. Circulation 1990; 82: 841-847.
9. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-223.
10. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
11. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-443.
12. Pelzer H, Schwartz A, Heimberger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbant assay. Thromb Haemost 1988; 59: 101-106.
13. Pelzer H, Schwartz A, Shiber W. Determination of human prothrombin activation fragment F 1 and 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159.
14. Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Semin Thromb Hemost 1987; 13: 514-527
15. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
16. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-192.
17. Geggel RL, Carvalho ACA, Hoyer LW, Reid LM. Von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135: 294-299.